Statement: Zantac (Ranitidine) Litigation – Gross Case
Statement: Zantac (Ranitidine) Litigation – Gross Case
GSK plc (LSE/NYSE: GSK) has reached a confidential settlement with Martin Gross resolving the case he filed in Illinois state court. GSK does not admit any liability in this settlement. The case will now be dismissed as to GSK.
GSK plc（LSE/NYSE: GSK）已与马丁·格罗斯达成保密和解，解决了他在伊利诺伊州法院提起的案件。GSK在此和解中不承认任何责任。该案件现已对GSK做出驳回裁定。
Following the 16 epidemiological studies looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.
在对人类有关雷尼替丁使用的16项流行病学研究后，科学共识是并没有一致或可靠的证据表明雷尼替丁增加任何癌症的风险。
GSK will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.
GSK将继续积极捍卫自己，并根据公司和股东的最佳利益管理此诉讼。
About GSK
关于GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
GSK是一家全球生物制药公司，以联合科学、技术和人才共同掌控疾病为宗旨。了解更多请访问gsk.com.
Cautionary statement regarding forward-looking statements
关于前瞻性声明的警告声明
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and GSK's Q1 Results for 2024.
GSK提醒投资者，GSK所作出的任何前瞻性声明或预测，包括本公告所作出的前瞻性声明或预测，均受到风险和不确定性的影响，可能导致实际结果与预期有所不同。这样的因素包括，但不限于，GSK2023年的年报20-F项目3.D“风险因素”和GSK2024年第一季度的业绩。